Bodycote (LSE:BOY) has published the scheme document for its board-backed cash Acquisition by a Veritas Capital-backed bidder, setting Shareholder meetings for 21 October 2026. On the same morning, rival Investment group CVC confirmed that it does not intend to make an offer.

What was announced

On 28 September 2026, Bodycote plc (LSE:BOY), the FTSE 250 heat treatment and thermal processing specialist, announced the publication of the scheme document for the proposed acquisition of the company by Vulcan Alpha Bidco Limited ("BidCo"). According to the announcement, BidCo is a newly formed company indirectly wholly owned by funds and investment vehicles managed or controlled by Veritas Capital Fund Management, L.L.C. The deal is to be implemented by a court-sanctioned scheme of arrangement.

The Bodycote directors unanimously support the scheme and are asking shareholders to vote in favour, and directors who hold shares have irrevocably undertaken to vote in favour of it.

At 07:00, ahead of the scheme document, CVC Advisers Limited issued a statement confirming that it does not intend to make an offer for Bodycote. A separate 07:45 disclosure table update removed CVC as a potential offeror, leaving Vulcan Alpha Bidco Limited as the only identified offeror.

The numbers

The terms were set out in the Rule 2.7 announcement of 1 September 2026. Shareholders are entitled to 940 pence per share, made up of 932.8 pence in cash from BidCo and a 7.2 pence FY26 Interim Dividend that shareholders may receive without any reduction in the cash price. That announcement valued Bodycote's fully diluted Share Capital at about £1,640 million on a cash basis (£1,652 million including the dividend), and implied an Enterprise value of about £1,840 million (£1,852 million including the dividend).

The 1 September announcement cited premia of 44.0% to Bodycote's closing price of 647.8 pence on 7 July 2026 and 24.3% to its closing price of 750.2 pence on 4 August 2026. Director irrevocables covered 252,480 shares, or about 0.15% of the issued capital. The latest disclosure table lists 170,187,993 ordinary shares in issue.

Background

The Offer Period began on 5 August 2026. Both Veritas and CVC made proposals for the company, and the 1 September announcement said CVC had submitted a proposal of 915 pence per share, including the permitted dividend, but had not proceeded to a firm offer. CVC was reported to have said it was evaluating its Options and told Bodycote shareholders to take no action.

CVC's statement of 28 September is made under Rule 2.8 of the Takeover Code. In general, this bars CVC from making an offer for Bodycote for six months. CVC may set this restriction aside in certain circumstances, including with the agreement of the Bodycote board if the Veritas offer is withdrawn or lapses, if a third party announces a firm intention to make an offer, or if the Takeover Panel determines there has been a material change of circumstances.

What to watch next

The Court Meeting is scheduled for 10:00 am and the General Meeting for 10:15 am on 21 October 2026, both at the Hilton London Paddington. At the Court Meeting, the scheme must be approved by a majority in number of scheme shareholders present and voting, representing 75% or more in value of the shares voted. The General Meeting requires the special resolution to be passed. The deadlines for proxy appointments are 10:00 am and 10:15 am on 19 October 2026 respectively.

The scheme is subject to regulatory and competition approvals and the other conditions set out in the scheme document. The expected timetable points to a court sanction hearing on 11 March 2027, or another date expected to fall in the first quarter of 2027. The long-stop date is 1 September 2027. If the scheme becomes effective, the timetable expects Bodycote's shares to be Delisted by 7:30 am three Business days after the sanction hearing.